IGXT Stock Overview
IntelGenx Technologies Corp., a drug delivery company, focuses on the development and manufacturing of novel oral thin film products for the pharmaceutical market.
Snowflake Score | |
---|---|
Valuation | 0/6 |
Future Growth | 0/6 |
Past Performance | 0/6 |
Financial Health | 2/6 |
Dividends | 0/6 |
IntelGenx Technologies Corp. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | US$0.15 |
52 Week High | US$0.22 |
52 Week Low | US$0.09 |
Beta | 2.48 |
1 Month Change | -11.00% |
3 Month Change | 6.19% |
1 Year Change | -20.06% |
3 Year Change | -73.17% |
5 Year Change | -71.43% |
Change since IPO | -40.00% |
Recent News & Updates
Recent updates
Shareholder Returns
IGXT | US Pharmaceuticals | US Market | |
---|---|---|---|
7D | -6.3% | 0.08% | 1.2% |
1Y | -20.1% | 13.2% | 24.9% |
Return vs Industry: IGXT underperformed the US Pharmaceuticals industry which returned 13.9% over the past year.
Return vs Market: IGXT underperformed the US Market which returned 24.7% over the past year.
Price Volatility
IGXT volatility | |
---|---|
IGXT Average Weekly Movement | 11.0% |
Pharmaceuticals Industry Average Movement | 9.8% |
Market Average Movement | 6.0% |
10% most volatile stocks in US Market | 16.6% |
10% least volatile stocks in US Market | 3.0% |
Stable Share Price: IGXT has not had significant price volatility in the past 3 months.
Volatility Over Time: IGXT's weekly volatility (11%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2003 | n/a | Dwight Gorham | www.intelgenx.com |
IntelGenx Technologies Corp., a drug delivery company, focuses on the development and manufacturing of novel oral thin film products for the pharmaceutical market. It offers INT0008/2008, a Rizatriptan oral film product for the treatment of migraine; INT0046/2018 and INT0055/2021 are for adult use; INT0007/2006, an oral film product for treatment of erectile dysfunction; INT0043/2015, an oral film containing montelukast for treatment of Alzheimer and Parkinsons; INT0027/2011 to treat opioid addition; INT0010/2006 for treatment of neuropathic pain and nausea in cancer patients undergoing chemotherapy; INT0036/2013, an oral film product for schizophrenia or bipolar 1 disorder; and INT0048/2020 for animal health. It is also develops INT0039/2013 for pain; and INT0053/2020 for the treatment of resistant depression.
IntelGenx Technologies Corp. Fundamentals Summary
IGXT fundamental statistics | |
---|---|
Market cap | US$28.63m |
Earnings (TTM) | -US$9.93m |
Revenue (TTM) | US$1.04m |
25.2x
P/S Ratio-2.6x
P/E RatioIs IGXT overvalued?
See Fair Value and valuation analysisEarnings & Revenue
IGXT income statement (TTM) | |
---|---|
Revenue | US$1.04m |
Cost of Revenue | US$1.73m |
Gross Profit | -US$694.00k |
Other Expenses | US$9.23m |
Earnings | -US$9.93m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
Earnings per share (EPS) | -0.057 |
Gross Margin | -66.80% |
Net Profit Margin | -955.44% |
Debt/Equity Ratio | -121.6% |
How did IGXT perform over the long term?
See historical performance and comparison